Ultragenyx sells additional 25% of Crysvita royalty interest for $400M

Ultragenyx (RARE) announced the sale, for $400M, of an additional 25% of the company’s royalty interest from Kyowa Kirin on the future sales of Crysvita in the United States and Canada to Omers. Omers will receive the additional 25% royalty interest on net sales of Crysvita beginning in January 2028. Pursuant to the new agreement, Omers will also continue to receive 30% of Crysvita net sales in the U.S. and Canada following the achievement of the 2022 royalty purchase agreement transaction’s cap of 1.45 times the purchase price. Total payments to Omers pursuant to the new agreement are capped at 1.55 times the purchase price.